RemeGen Co., Ltd. (Stock Code: 9995) released an announcement regarding a series of renewals for its continuing connected transactions and one-off connected transactions. According to the document, multiple existing agreements will expire on December 31, 2025, and the company plans to extend them for three years starting January 1, 2026, subject to relevant approvals.

The renewed continuing connected transactions include the 2026–2028 MabPlex Master Service Agreement, 2026–2028 Materials Purchase Framework Agreement, 2026–2028 MabPlex Property Lease Agreement, 2026–2028 CRC Services Framework Agreement, and 2026–2028 General Services Framework Agreement. These involve service supply, property leases, materials purchases, and related arrangements with MabPlex, CelluPro, RC Pharma, Yeda Incubation, and Kangkang. The announcement highlights new annual caps for the corresponding services and products, alongside the company’s rationale for each transaction, such as continued research, manufacturing demands, or efficiency in facility usage.

Additionally, the announcement addresses renewals of one-off connected transactions through the 2026 Equipment Lease Agreement, 2026 Yeda Incubation Building Lease, and 2026 MabPlex Apartment Lease Agreement. The company expects to lease more equipment in certain areas while reducing the space in others due to changing business requirements. These transactions will be treated as acquisitions of right-of-use assets in the company’s accounts under IFRS 16.

All relevant agreements are subject to compliance with applicable percentage ratios under the Listing Rules and to reporting, annual review, announcement, and in some cases independent shareholders’ approval. RemeGen will convene an extraordinary general meeting to consider and vote on the corresponding resolutions. The circular containing further details and the EGM notice will be made available in due course.